TheraPsil, a Canadian coalition for psilocybin therapy legalization, together with the U.K. independent foundation Drug Science, has launched Project Solace.
The goal is to gather data to better inform patients about the development of regulated psilocybin products. That way it can document clinical effectiveness, safety, clinician and patient-reported outcomes in those receiving medical psilocybin-assisted psychotherapy via the Canadian Special Access Programme (SAP) or under exemptions that authorize psilocybin possession.
